Fluticasone propionate
- Generic Name
- Fluticasone propionate
- Brand Names
- Advair, Airduo, Airduo Respiclick, Aller-flo, Armonair, Beser, Cutivate, Dymista, Flonase, Flovent, Fluticare, Ticanase, Wixela, Xhance
- Drug Type
- Small Molecule
- Chemical Formula
- C25H31F3O5S
- CAS Number
- 80474-14-2
- Unique Ingredient Identifier
- O2GMZ0LF5W
- Background
Fluticasone propionate is a synthetic glucocorticoid. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications. Fluticasone propionate was first approved in 1990.
- Indication
Fluticasone propionate is indicated as an inhaler for the treatment and management of asthma by prophylaxisas well as inflammatory and pruritic dermatoses. Fluticasone propionate nasal spray is indicated for managing allergic and nonallergic rhinitis.
- Associated Conditions
- Allergic Rhinitis (AR), Allergy to Animal Dander, Allergy to Mold, Allergy to Tree Pollen, Asthma, Bacterial Sinusitis, Chronic Bronchitis, Chronic Obstructive Pulmonary Disease (COPD), Chronic Sinusitis, Dermatitis, Emphysema, Eosinophilic Esophagitis, House Dust Mite Allergy, House dust allergy, Itching of the nose, Nasal Congestion, Non-Allergic Rhinitis, Rhinitis, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Moderate, severe Perennial Allergic Rhinitis (PAR), Moderate, severe Seasonal Allergic Rhinitis
Mometasone Furoate Aqueous (MK-0887/SCH 032088) Nasal Spray vs Placebo and FLONASE® in Seasonal Allergic Rhinitis Patients (I94-001)
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- First Posted Date
- 2019-03-20
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 313
- Registration Number
- NCT03882047
Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent® HFA 110 mcg
- Conditions
- Asthma
- Interventions
- Drug: Placebo pressurized metered dose inhaler
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2021-09-01
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 1902
- Registration Number
- NCT03879837
- Locations
- 🇺🇸
Site 1, Spartanburg, South Carolina, United States
Study Evaluating the Efficacy and Safety of Intranasal Administration of OPN-375 in Subjects With Chronic Rhinosinusitis With or Without the Presence of Nasal Polyps
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 332
- Registration Number
- NCT03781804
- Locations
- 🇺🇸
Emory University MOT, Atlanta, Georgia, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸John Hopkins Hospital, Baltimore, Maryland, United States
EoE RCT Fluticasone and Omeprazole vs Fluticasone Alone
- Conditions
- Eosinophilic Esophagitis
- Interventions
- Diagnostic Test: Retrospective evaluation of endoscopy prior to study drugOther: Symptom SurveyOther: Medication Compliance Phone CallDiagnostic Test: Endoscopy while on study drugDrug: Placebo oral capsule
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2018-12-20
- Lead Sponsor
- Claire Daniels
- Target Recruit Count
- 100
- Registration Number
- NCT03781596
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma
- Conditions
- Asthma
- Interventions
- Drug: Placebo Inhalation Powder
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2021-09-24
- Lead Sponsor
- Actavis Inc.
- Target Recruit Count
- 999
- Registration Number
- NCT03756883
- Locations
- 🇺🇸
Study Site 101, Miami Lakes, Florida, United States
A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers
- Conditions
- Bioequivalence
- Interventions
- First Posted Date
- 2018-11-23
- Last Posted Date
- 2018-12-28
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT03751202
- Locations
- 🇬🇷
BECRO Clinical Facility, Larissa, Thessaly, Greece
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
- First Posted Date
- 2018-11-20
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Optinose US Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT03747458
- Locations
- 🇺🇸
Arizona Allergy and Immunology Research, Gilbert, Arizona, United States
🇺🇸Children's Minnesota, Minneapolis, Minnesota, United States
🇺🇸Eastern Virginia Medical School - Otolaryngology, Norfolk, Virginia, United States
Urine Concentrations of Vilanterol After Inhaled Administration of Vilanterol/Fluticasone Furoate
- Conditions
- Pharmacokinetics
- Interventions
- First Posted Date
- 2018-11-13
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Bispebjerg Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT03739294
- Locations
- 🇩🇰
Respiratory research unit, Bispebjerg University Hospital, Copenhagen, Denmark
A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2018-09-18
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Respirent Pharmaceuticals Co Ltd.
- Target Recruit Count
- 451
- Registration Number
- NCT03676413
- Locations
- 🇬🇷
BECRO Ltd., Athens, Greece
DYmista NAsal Spray in CHInese Patients
- Conditions
- Allergic Rhinitis
- Interventions
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2022-02-22
- Lead Sponsor
- MEDA Pharma GmbH & Co. KG
- Target Recruit Count
- 900
- Registration Number
- NCT03599791
- Locations
- 🇨🇳
Investigational Site 3, Tianjin, Tianjin, China
🇨🇳Investigational Site 1, Tianjin, Tianjin, China
🇨🇳Investigational Site 2, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.